InvestorsHub Logo
Followers 32
Posts 5818
Boards Moderated 0
Alias Born 05/23/2006

Re: r622102675 post# 330250

Wednesday, 05/08/2019 9:03:55 AM

Wednesday, May 08, 2019 9:03:55 AM

Post# of 345961
yes part of the issue was biosimilars cutting into roche products.. from reading halo investor presentation, enhaze could allow reformulation w new patent protection... so short term blip imo and not fully researched... what is gaining traction is the delivery mode of enhaze which makes treatment a lot faster and more efficient vs IV delivery...
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News